By Dr. Amitha Parvataneni

TL;DR

This is the third and final post in a series that started with an FDA peptide hearing touching our hair-restoration and peptide programs, moved through hormone replacement therapy, and now looks at where physician-supervised peptide therapy for longevity and recovery is actually headed.
On July 23 and 24, 2026, an FDA advisory committee voted to recommend six of the seven peptides it reviewed, including BPC-157 and Mots-C, for the list that lets licensed compounding pharmacies prepare them on a prescription.^[1][2][3] That is a recommendation, not a finalized rule, and as of this writing the FDA has not finalized it.^[2][3]
"Longevity" and "recovery" are having a real moment in medicine and in marketing right now. Some of that excitement is backed by strong evidence. A meaningful amount of it is not there yet, and I would rather tell you which is which than let a trend do the talking.
We offer BPC-157 and Mots-C through a physician-supervised program, but I am not going to tell you either one is proven to treat a specific condition. That evidence base is still developing.^[1][6]
Whether you are here for hair restoration, hormone therapy, or a peptide, the same rule applies in this office: a real evaluation, responsible sourcing, honest expectations, and a physician who stays involved.

Three Posts, One Underlying Question
Where the FDA Peptide Story Stands Today
What "Longevity Medicine" Actually Means
Where the Evidence Is Strong, and Where It Is Still Developing
What Physician Supervision Actually Changes
What This Means If You Are Considering Any of This
Frequently Asked Questions
Research Appendix

If you have spent any time online lately, you have probably seen the word "longevity" everywhere. Peptides, recovery stacks, longevity supplements, protocols that promise to slow aging or speed healing. Maybe it excites you. Maybe it makes you skeptical. Honestly, both reactions are reasonable.

This is the third piece in a series I started this summer after an FDA peptide hearing raised real questions for anyone considering hair restoration, hormone therapy, or a peptide program like ours. My first post walked you through what that hearing actually was. My second post covered what the committee's vote actually meant, and what it did not.

This one steps back and answers the bigger question underneath all of it. Where is peptide therapy for longevity and recovery actually headed, and how much of what you are seeing online is real? I am going to tell you plainly what the evidence supports today, what it does not yet support, and why physician supervision is the biggest variable in how safely you can explore any of it.

Three Posts, One Underlying Question

Three posts, one question underneath all of them. Is a treatment personalized and physician-supervised, or is it generic and gray-market? That question started this series back in July, when an FDA advisory committee's hearing on peptide compounding made headlines and directly touched two things we offer in this office: TED hair restoration and our peptide program.^[13]

The first post in this series walked through what TED hair restoration actually is, an FDA-cleared ultrasound device, not a self-injected drug, and introduced the two peptides in our own supervised program by name, BPC-157 and Mots-C.^[7][13] The second post covered the committee's actual vote once it happened, and was just as direct about what that vote did and did not change.^[14]

This post is where I want to zoom out. Whether the topic is a hair-restoration device, a hormone replacement plan, or a peptide protocol marketed for longevity and recovery, the same question follows you into every decision: who is standing between you and this treatment, and what are they actually doing to keep you safe?

Where the FDA Peptide Story Stands Today

If you read either of my first two posts, here is the two-sentence recap. On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six of the seven peptides it reviewed, including BPC-157 and Mots-C, for the list that lets licensed compounding pharmacies prepare them on a prescription. BPC-157 passed 8 to 6. Mots-C passed 7 to 5.^[1][2][3]

The FDA's own career scientists had recommended against this move before the vote, citing an evidence base that leans heavily on animal and lab studies rather than human trials. The advisory committee voted to recommend it anyway.^[4][5][6]

Here is the part that has not changed, and it is worth sitting with. A committee vote is a recommendation, not a rule. The FDA and HHS still have to take formal action before anything actually changes for compounding pharmacies, and as of this writing, that formal action has not been finalized.^[2][3]

I want to be just as honest about the limits of what I can tell you here. Regulatory timelines like this one can move slowly, and I do not have a crystal ball for exactly when, or whether, a final rule lands. What has not changed regardless of that timeline is this: we have never treated BPC-157 or Mots-C as a self-directed purchase, and we are not going to start once a final rule does land either.^[14]

What "Longevity Medicine" Actually Means

"Longevity medicine" is a term you are going to keep seeing, so let's define it plainly. At its best, it means using real, measurable tools, lab work, imaging, targeted therapies, to help your body function better for longer. Think of it like a mechanic running an actual diagnostic on your car versus someone guessing which part might be the problem. One approach is grounded in data. The other is a guess with a confident voice attached to it.

At its worst, "longevity medicine" is a marketing label slapped on a product with little evidence behind it, sold with the promise that it will slow aging itself.

Peptides sit right in the middle of that spectrum, which is exactly why this conversation matters. Some peptides are rigorously studied, FDA-approved medications. Tirzepatide and semaglutide went through years of clinical trials before reaching a pharmacy.^[13] Others, including the ones named in this summer's FDA hearing, are compounded substances with a much thinner human evidence base, sold online under the same broad "longevity" umbrella with far less oversight.^[1][6]

"Recovery" gets the same treatment. Active patients are drawn to peptides and growth-factor treatments because the underlying idea, helping the body repair itself more efficiently, is genuinely appealing. Some of that field is well-supported. A lot of it is still in the early stages of real research.

Where the Evidence Is Strong, and Where It Is Still Developing

I would rather walk you through this honestly than let a trend do the talking, because that is the standard I try to hold in every post in this series.

Where the evidence is strong: FDA-cleared devices and FDA-approved medications. TED hair restoration uses an FDA-cleared ultrasound device to deliver a topical peptide and growth-factor blend to the scalp, and the early clinical evaluations behind it are real, even if they are still small. One evaluation of 33 patients found meaningful increases in hair density at six months, and a separate evaluation of 10 patients reported similar improvement with no adverse events.^[7][8][9]

Testosterone therapy for postmenopausal women also has real, consensus-backed evidence behind it, for one specific use: treating low sexual desire, when dosed carefully to natural levels and monitored by a physician.^[10] And the broader research on hormone replacement therapy has shifted meaningfully in recent years. A major 2024 reassessment of the original Women's Health Initiative data, along with the FDA's own November 2025 decision to remove broad black-box warnings from many HRT products, both point toward benefits that meaningfully outweigh the risks for many women, especially those who start therapy younger than 60 or within 10 years of menopause.^[11][12]

Where the evidence is still developing: peptides like BPC-157 and Mots-C, and a good deal of what gets marketed under the "longevity" and "recovery" banner generally. In the wellness world, BPC-157 is often discussed for inflammation and recovery, and Mots-C for metabolism and energy. I am not going to tell you either one is proven to treat a specific condition, because the human research behind both is still developing, the exact gap the FDA's own scientists pointed to even as the advisory committee voted to move forward anyway.^[1][6][14]

That is not a reason to dismiss them. It is a reason to be honest about where they actually sit today, and to make sure a physician, not a headline or an online seller, is the one guiding your decision.

Here is the honest bottom line, and I think you deserve to hear it plainly. Some of what excites me about where peptide medicine is headed is genuinely well-supported. Some of it is still unproven. I am not going to blur that line to make either sound more exciting than it actually is, and I would ask the same of anyone else offering you one of these treatments.

What Physician Supervision Actually Changes

Every section above points to the same conclusion. The safest question to ask about any longevity or recovery treatment was never just "is this legal" or "is this trending." The more useful question is who is standing between you and this substance or device, and what are they actually doing to keep you safe.

In this office, that means every peptide patient starts with a real consultation before anything is prescribed, not a checkout cart. It means sourcing through a licensed compounding pharmacy rather than an anonymous online seller shipping a vial with no prescription attached.^[14]

It means every hormone replacement therapy patient starts with real lab work, not a standard starter kit, and a plan built around your own results rather than a one-size-fits-all protocol.^[15] And it means TED hair restoration happens here, in our office, applied by our team, under my supervision, using a device that is FDA-cleared rather than a formula ordered online and applied at home.^[7]

None of that changes based on which way a regulatory vote goes, or which peptide is trending this month. It is simply how I practice medicine.

What This Means If You Are Considering Any of This

If you are curious about hair restoration, hormone therapy, or a peptide protocol, here is what I would actually tell you to do, not as a sales pitch, but as the physician who would be sitting across from you.

Start with a real evaluation, not a product. Ask whoever is offering you a treatment how they source it, and whether they stay involved after that first purchase. Ask directly what the evidence does and does not show for the specific thing you are considering, and notice whether you get a straight answer or a marketing one.

If hormone therapy feels like the more pressing question for you right now, a virtual consultation is a real conversation with me by video, not a generic questionnaire.^[15] If hair restoration is the more pressing question, an in-person TED consultation lets us evaluate your specific pattern of thinning before we talk about whether it is a fit.^[7][13]

And if you are exploring a peptide protocol for longevity or recovery, that conversation starts the same way both of those do: with an honest look at you, not a trend.

Frequently Asked Questions

What is peptide therapy for longevity and recovery, exactly? "Peptide therapy" is not one treatment. It covers a wide range of injectable or topical compounds, from FDA-approved medications like tirzepatide to compounded substances like BPC-157 and Mots-C that are still being studied.^[1][13] "Longevity and recovery" is more of a goal than a specific product: using well-supervised tools to help your body function and heal as well as it can. Whether a specific peptide "works" depends entirely on which one, and which specific claim, you are asking about.

Is BPC-157 or Mots-C proven to work for anti-aging or recovery? No, not in the sense of a proven, FDA-approved indication. In the wellness world, BPC-157 is often discussed for inflammation and recovery, and Mots-C for metabolism and energy, but the human research behind both is still developing.^[1][6][14] We offer both through a physician-supervised program because we believe in doing this responsibly if a patient chooses to pursue it, not because either one is a proven cure for anything.

Did the FDA finalize its decision on peptide compounding? As of this writing, no. An FDA advisory committee voted on July 23 and 24, 2026 to recommend easing compounding restrictions on six of seven reviewed peptides, including BPC-157 and Mots-C, but that vote is a recommendation to the FDA, not a final rule.^[1][2][3] The FDA and HHS have not yet finalized formal action. If that changes, we will update this series.

How is TED hair restoration different from a peptide protocol? TED stands for TransEpidermal Delivery. It is an FDA-cleared ultrasound device that delivers a topical peptide and growth-factor blend to the scalp, applied in our office.^[7] It is not injected, and it is not the same as our separate peptide program, which uses injectable compounds like BPC-157 and Mots-C for different goals. Both are physician-supervised, but they serve different purposes.

How do I know if physician-supervised peptide therapy is right for me? The only honest way to know is a real consultation. We would look at your health history and your specific goals, whether hair restoration, hormone therapy, or a peptide protocol, and give you a straight answer about what the evidence actually supports for your situation, not just what sounds appealing.

Research Appendix

[1] Stone, Will. "FDA advisers vote to ease peptide restrictions, despite agency concerns." NPR, July 23, 2026.
[2] "In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides." STAT News, July 23, 2026.
[3] "Advisers to the FDA back broad access to unapproved peptides, despite agency concerns." KPBS, July 23, 2026.
[4] "FDA advisory committee backs two more peptides, rejects one for compounding list." RAPS, July 24, 2026.
[5] "An FDA Committee Just Voted in Favor of Peptides Despite the Agency's Opposition." TIME, July 23, 2026.
[6] Jewett, Christina and Dana G. Smith. "A Peptide Showdown: F.D.A. Scientists May Clash With Kennedy's Agenda." The New York Times, July 23, 2026.
[7] U.S. Food and Drug Administration, 510(k) Premarket Notification Database. "Alma TED+ System," K251684, Alma Lasers, Inc., decision date June 5, 2026, device class II. fda.report/PMN/K251684.
[8] Bauman, DiBernardo B, Desai S. "A 6-Month Dual-Center Study Evaluating Alma TED and a Peptide-Based Topical Hair Care Formula for Female and Male Pattern Hair Loss." Manufacturer-supported clinical evaluation, N=33. White paper.
[9] DiBernardo B, Dy L, Desai S. "Transepidermal Delivery With a Proprietary Low-Frequency Ultrasound: A New Novel Treatment Option for Androgenetic Alopecia?" Clinical evaluation, N=10. Study PDF.
[10] Davis SR, Baber R, Panay N, et al. "Global Consensus Position Statement on the Use of Testosterone Therapy for Women." The Journal of Clinical Endocrinology & Metabolism, 2019;104(10):4660-4666. doi.org/10.1210/jc.2019-01603.
[11] "HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy." U.S. Food and Drug Administration, November 10, 2025. HHS press room.
[12] Manson JE, Crandall CJ, Rossouw JE, et al. "The Women's Health Initiative Randomized Trials and Clinical Practice: A Review." JAMA, 2024. Summary via National Institutes of Health / NHLBI. NHLBI.
[13] Parvataneni, Amitha. "Hair Restoration, Hormone Therapy, and Peptides: What You Should Know This Week." ASM.D. Aesthetics, July 23, 2026.
[14] Parvataneni, Amitha. "Is BPC-157 Legal Now? What the FDA Advisory Committee's Vote Actually Means." ASM.D. Aesthetics, July 27, 2026.
[15] Parvataneni, Amitha. "When the Doctor Becomes the Patient: How My Own HRT Journey Changed Everything." ASM.D. Aesthetics, July 15, 2026.

These sources include peer-reviewed journal articles, an FDA regulatory database record, contemporaneous news reporting on the July 2026 FDA advisory committee hearing, and manufacturer-supported clinical evaluations. They are not all peer-reviewed research, and where the evidence is preliminary or manufacturer-supported, that is noted directly in the text above.

One Conversation Is Worth More Than Any Trend

You do not need a medical degree to ask good questions about what goes into your body, or about what a trend online actually means for you. That is true whether the trend is a headline about an FDA vote or a peptide protocol promising to change how you age.

I can only speak for what happens in this office. Every hair-restoration patient, every hormone therapy patient, and every peptide patient starts with a real evaluation, a real plan, and a physician who stays involved and stays honest about what the evidence does and does not yet show. That will not change no matter what the next trend is, or how the FDA's final decision eventually lands.

To find out whether physician-supervised TED hair restoration is right for you, schedule an in-person consultation with Dr. Amitha Parvataneni at ASMD Aesthetics.

Call us: (313) 949-0418
Learn more about hair restoration: asmdaesthetics.com/hair-restoration
Book your free TED consultation online: Schedule here

If hormone replacement therapy, or a physician-supervised peptide program, is the more pressing question for you, start with a virtual HRT consultation, from wherever you are.

Book your virtual HRT consultation online: Schedule here
Read the rest of this series: Post 1: Hair Restoration, Hormone Therapy, and Peptides and Post 2: Is BPC-157 Legal Now?

The Future of Peptide Therapy: What's Actually Proven for Longevity and Recovery (and What Isn't Yet)